Saturday, 31 October 2026European Markets

CHAUSSERIA Stock Falls 9% So Far On Friday, Underperforms Market

Loading stream...

chausseria (cac 40: chsr.pa) experienced an 8.99% stock decline to eur10.00 on friday, in line with cac 40's 1.01 drop to eur7,118.88 after three consecutive losses. despite today's difficulties, chausseria remains resilient, boasting an astounding 37.5% surge from its 52-week high of eur8.00, reflecting investors' belief in their french women's shoe designer and manufacturer.

chausseria's financial health

profitability measures of this firm appear strong, with a trailing twelve months earnings per share (eps) of eur0.39. prospective buyers appear optimistic, investing eur25.64 for each euro of annual earnings as evidenced by an attractive price/earnings ratio of 25.64; such an optimistic figure can signal investor optimism regarding future growth prospects of an enterprise.

concerns over low return on equity

however, shareholders may be concerned over the company's low return on equity (roe) of 4.29% which suggests less efficient profits-generation processes within it.

declining revenue growth

chausseria's declining revenue growth should cause concern; their year-on-year decrease has reached 8.9% and could indicate that the company may face challenges keeping its business going in an unstable market environment.

stock performance

chausseria's stock is encouragingly above both its 50-day moving average of eur5.16 and 200-day moving average of eur5.20. this indicates an upward trend in value, which bodes well for longer-term performance.

high volatility levels

investors should expect significant price swings, given chausseria's high volatility levels - 7.83% last week and 18.54% over the last quarter - which suggest significant price fluctuations. investors with an aversion to risk should take this factor into consideration when making their decisions about chausseria investments.

in conclusion, chausseria presents an unpredictable investment landscape, with steady profitability measures and increasing stock prices partially offsetting declining revenues and considerable price volatility concerns.

more news about chausseria (chsr.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com